Amylyx Pharmaceuticals (AMLX) Non-Current Assets (2021 - 2026)

Amylyx Pharmaceuticals' Non-Current Assets history runs 6 years deep, the most recent figure standing at $8.6 million for Q1 2026.

• On a quarterly basis, Non-Current Assets rose 142.89% year-over-year to $8.6 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 85.88% increase from a year earlier, with the FY2025 full-year figure at $9.0 million, up 113.56% from the prior year.
• Non-Current Assets slipped to $8.6 million in Q1 2026 per AMLX's latest filing, from $9.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $52.8 million in Q4 2023 and bottomed at $3.5 million in Q1 2025.
• The 5-year median for Non-Current Assets is $9.0 million (2025), against an average of $13.4 million.
• Across the five-year window, Non-Current Assets jumped 1305.73% in 2022 and sank 92.04% in 2024, its largest moves.
• Year by year, Non-Current Assets stood at $9.3 million in 2022, then jumped by 466.39% to $52.8 million in 2023, then sank by 92.04% to $4.2 million in 2024, then jumped by 113.56% to $9.0 million in 2025, then fell by 4.4% to $8.6 million in 2026.
• Per Business Quant, the three latest AMLX Non-Current Assets figures stand at $8.6 million (Q1 2026), $9.0 million (Q4 2025), and $9.4 million (Q3 2025).